Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation | Zendy

Chang Liu | Zendy; Miao Wang | Zendy; Changli Xu | Zendy; Bo Li | Zendy; Juxiang Chen | Zendy; Jianchun Chen | Zendy; Zhiwei Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation

Author(s) -

Chang Liu,

Miao Wang,

Changli Xu,

Bo Li,

Juxiang Chen,

Jianchun Chen,

Zhiwei Wang

Publication year - 2021

Publication title -

journal of immunology research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.315

H-Index - 83

eISSN - 2314-8861

pISSN - 2314-7156

DOI - 10.1155/2021/8970173

Subject(s) - medicine , immunotherapy , bone metastasis , tumor microenvironment , immune system , metastasis , breast cancer , cancer , oncology , cancer research , melanoma , immune checkpoint , prostate cancer , renal cell carcinoma , immunology

The treatment of bone metastases is a thorny issue. Immunotherapy may be one of the few hopes for patients with unresectable bone metastases. Immune checkpoint inhibitors are the most commonly used immunotherapy drugs currently. In this review, the characteristics and interaction of bone metastases and their immune microenvironment were systematically discussed, and the relevant research progress of the immunological mechanism of tumor bone metastasis was reviewed. On this basis, we expounded the clinical application of immune checkpoint inhibitors for bone metastasis of common tumors, including non-small-cell lung cancer, renal cell carcinoma, prostate cancer, melanoma, and breast cancer. Then, the deficiencies and limitations in current researches were summarized. In-depth basic research on bone metastases and optimization of clinical treatment is needed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research